Latest News

DXC impulsa los seguros inteligentes

Sands China Launches 'NBA Cares x Sands Cares Community Impact Week 2026'

Pearl Diagnostics Announces Publication of Clinical Studies Supporting FDA Clearance of MycoMEIA ® Aspergillus Assay

Priority Technology Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Priority Technology Holdings, Inc. - PRTH

Rosen Law Firm Encourages The Ensign Group, Inc. Investors to Inquire About Securities Class Action Investigation - ENSG

Pinnacle Financial Partners CEO Kevin Blair and CFO Jamie Gregory to hold fireside chat at BancAnalysts Association of Boston Conference

Breast Cancer Awareness Month Raises Questions About Antipsychotic Drug Warnings

AARD Deadline: Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Calgon Carbon Marks Major Expansion of Texas Facility, Nearly Doubling Reactivated Carbon Output Capacity

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)